Announcements Trials

Browse Landscape Eligibility

Clinical Trials

0 trials

Recent Start date Enrollment

Carcinoma, Hepatocellular × eribulin × 1 year × Clear all

Sponsor

Conditions

Breast Neoplasms 24 Triple Negative Breast Neoplasms 10 Sarcoma 5 Neoplasm Metastasis 5 Liposarcoma 3 Inflammatory Breast Neoplasms 3 Urinary Bladder Neoplasms 2 Leiomyosarcoma 2 Carcinoma, Transitional Cell 2 Uterine Cervical Neoplasms 1 Urethral Neoplasms 1 Ureteral Neoplasms 1 Refractory Solid Tumors 1 Recurrence 1 Ketosis 1 Histiocytoma, Malignant Fibrous 1 Hemangiosarcoma 1 Hemangioendothelioma, Epithelioid 1 HR+HER2- Breast Cancer 1 HER2-negative Metastatic Breast Cancer 1 HER2-low Breast Cancer 1 Fludzoparib" and Anti-angiogenic 1 Colorectal Neoplasms 1 Brest Cancer 1 Brain Neoplasms 1 Advanced Breast Cancer 1

Interventions

Bevacizumab 59 atezolizumab 51 durvalumab 37 lenvatinib 35 pembrolizumab 33 Nivolumab 28 tremelimumab 23 Magnetic Resonance Spectroscopy 18 Specimen Handling 16 Sorafenib 16 Ipilimumab 13 tislelizumab 12 regorafenib 12 cabozantinib 12 apatinib 11 Radiosurgery 11 Immune Checkpoint Inhibitors 11 sintilimab 10 camrelizumab 9 Blood Specimen Collection 9 Radiotherapy 8 Immunoglobulin G 7 Cyclophosphamide 7 X-Rays 6 Hepatectomy 6 Disulfides 6 donafenib 5 Surgical Procedures, Operative 5 Fluorouracil 5 fludarabine 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

No trials found.

Data powered by HemOnc (CC BY 4.0) Colophon ⚡